Treatment of cancer with HER2XCD3 bispecific antibody and anti-HER2 MAB in combination

摘要

The present invention uses a HER2 antibody, such as a HER2 T cell-dependent bispecific antibody (TDB) in combination with an additional HER2 antibody (eg, trastuzumab) for HER2-positive cancers (eg, HER2-positive breast cancer and HER2). -Provides a method of treating benign gastric cancer).